Literature DB >> 23403632

Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.

Geoffrey R Oxnard1, Pasi A Jänne.   

Abstract

Widespread tumor genotyping has increased the complexity of lung cancer care, often identifying mutations of uncertain clinical significance. In the accompanying article, the authors carried out a meta-analysis of the published literature on EGF receptor (EGFR) genotype and erlotinib/gefitinib sensitivity to develop a publicly accessible database to inform patient care. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23403632      PMCID： PMC4327821          DOI： 10.1158/1078-0432.CCR-13-0169

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  9 in total

1.  Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.

Authors:  Kazuyuki Tsujino; Tomoya Kawaguchi; Akihito Kubo; Nana Aono; Keiko Nakao; Yasuhiro Koh; Kazunobu Tachibana; Shun-Ichi Isa; Minoru Takada; Takayasu Kurata
Journal:  J Thorac Oncol       Date:  2009-08       Impact factor: 15.609

2.  EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.

Authors:  Mai He; Marzia Capelletti; Khedoudja Nafa; Cai-Hong Yun; Maria E Arcila; Vincent A Miller; Michelle S Ginsberg; Binsheng Zhao; Mark G Kris; Michael J Eck; Pasi A Jänne; Marc Ladanyi; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2011-12-21       Impact factor: 12.531

3.  Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

Authors:  Jenn-Yu Wu; Chong-Jen Yu; Yeun-Chung Chang; Chih-Hsin Yang; Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2011-04-29       Impact factor: 12.531

4.  Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Authors:  Qing Zhou; Xu-Chao Zhang; Zhi-Hong Chen; Xiao-Lu Yin; Jin-Ji Yang; Chong-Rui Xu; Hong-Hong Yan; Hua-Jun Chen; Jian Su; Wen-Zhao Zhong; Xue-Ning Yang; She-Juan An; Bin-Chao Wang; Yi-Sheng Huang; Zhen Wang; Yi-Long Wu
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

5.  Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR.

Authors:  Kuei-Pin Chung; Shang-Gin Wu; Jenn-Yu Wu; James Chih-Hsin Yang; Chong-Jen Yu; Pin-Fei Wei; Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2012-04-17       Impact factor: 12.531

6.  Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

Authors:  Geoffrey R Oxnard; Peter C Lo; Mizuki Nishino; Suzanne E Dahlberg; Neal I Lindeman; Mohit Butaney; David M Jackman; Bruce E Johnson; Pasi A Jänne
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

7.  DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.

Authors:  Paul Yeh; Heidi Chen; Jenny Andrews; Riyad Naser; William Pao; Leora Horn
Journal:  Clin Cancer Res       Date:  2013-01-23       Impact factor: 12.531

8.  Screening for germline EGFR T790M mutations through lung cancer genotyping.

Authors:  Geoffrey R Oxnard; Vincent A Miller; Mark E Robson; Christopher G Azzoli; William Pao; Marc Ladanyi; Maria E Arcila
Journal:  J Thorac Oncol       Date:  2012-06       Impact factor: 15.609

9.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer.

Authors:  Simon A Forbes; Gurpreet Tang; Nidhi Bindal; Sally Bamford; Elisabeth Dawson; Charlotte Cole; Chai Yin Kok; Mingming Jia; Rebecca Ewing; Andrew Menzies; Jon W Teague; Michael R Stratton; P Andrew Futreal
Journal:  Nucleic Acids Res       Date:  2009-11-11       Impact factor: 16.971
  9 in total
  3 in total

1.  Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

Authors:  M Beau-Faller; N Prim; A-M Ruppert; I Nanni-Metéllus; R Lacave; L Lacroix; F Escande; S Lizard; J-L Pretet; I Rouquette; P de Crémoux; J Solassol; F de Fraipont; I Bièche; A Cayre; E Favre-Guillevin; P Tomasini; M Wislez; B Besse; M Legrain; A-C Voegeli; L Baudrin; F Morin; G Zalcman; E Quoix; H Blons; J Cadranel
Journal:  Ann Oncol       Date:  2013-11-26       Impact factor: 32.976

Review 2.  Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.

Authors:  Yoshihisa Kobayashi; Tetsuya Mitsudomi
Journal:  Cancer Sci       Date:  2016-08-09       Impact factor: 6.716

3.  Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.

Authors:  Yan Zhang; Zheng Wang; Xuezhi Hao; Xingsheng Hu; Hongyu Wang; Yan Wang; Jianming Ying
Journal:  Chin J Cancer Res       Date:  2017-02       Impact factor: 5.087
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.